Advanced models, such as KrasG12D/+/p53fl/+ mutant mice, demonstrate that IL-6-neutralizing antibodies significantly reduce the growth of early-stage PDAC lesions, highlighting the potential importance of IL-6 in tumor initiation [226]. The gene discussed is IL6; the disease is neoplasm.